Open AccessDurvalumab + Tremelimumab Improves Survival in Metastatic NSCLC
Author(s) -
Mark L. Fuerst
Publication year - 2021
Publication title -
oncology times
Language(s) - Uncategorized
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000796024.26126.5e
Subject(s) - tremelimumab , durvalumab , medicine , oncology , lung cancer , chemotherapy , cancer , immunotherapy , nivolumab , ipilimumab